alexa Suggestions For Overcoming The Problems With Biosimilars In The United States
ISSN: 1948-593X

Journal of Bioanalysis & Biomedicine
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

3rd International Conference and Exhibition on Biowaivers, Biologics & Biosimilars
October 27-29, 2014 Hyderabad International Convention Centre, Hyderabad, India

Jim Nelson
Accepted Abstracts: J Bioanal Biomed
DOI: 10.4172/1948-593X.S1.015
The US lags far behind Europe in authorizing BioSimilars. The problem sits squarely on the doorstep of the legal process for gaining Biosimilar approval in the US. Unlike a Generic Pharmaceutical, a BioSimilar can exhibit substantial differences from the registered Biological. Such differences give rise to the authorization difficulties but may also make the BioSimilar patentable. Clear sailing through the US Patent Office for a Biological is not assured however. For example, the U.S. Supreme Court and the Patent Office have laid down rules that restrict the patenting of natural products. Proof may be needed that a Biological composition is non-obvious in view of the Registered Biological. In this presentation the author will address will address these issues and provide suggestions for overcoming them. The legal process for gaining approval for sale of a BioSimilar in the US is two-fold: FDA approval of the BioSimilar and successfully wading through the patent quagmire protecting the Registered Biological. The FDA requirements for BioSimilar approval differ substantially from FDA requirements for approval of a Generic Pharmaceutical. Biotech companies explain that long and complicated clinicals as well as certification of the production variability of the Biological are required. The patent blockage is also difficult. Unlike the Hatch Waxman law which makes the service of the Paragraph IV letter an artificial act of infringement and which brings on the lawsuit, the BioSimilars Laws looks to the parties to initiate a patent dispute. In several recent examples, BioSimilar companies attempted to bring on the lawsuit through declaratory judgment actions only to be thrown out of court because the dispute was deemed "premature." We will discuss such flash points in the legal process for US approval of BioSimilars. Not only are Biologicals brews of several or many components but they vary from batch to batch. The US FDA recognizes this difficulty and has promulgated substantial requirements for BioSimilars approval based upon the clinicals for the Registered Biological. However, the very differences and difficulties in making safe and active products provide an opportunity to obtain US Patents for BioSimilar products. Prosecution of a BioSimilar patent application in the US has special needs and pitfalls, not the least of which are the new PTO regulations and rules concerning the patenting of natural products. While the old guideline enabled patenting of a Biological isolated from nature, no longer is this apparently possible because of Myriad and the new US Patent Office rules. Why should a BioSimilar be patented? The short answer is simple: Keep other Biological Generics from copying your product. The long answer depends upon costs, timing, profitability and assessment of the alternative to patenting: keeping the details of the BioSimilar and its process as trade secrets. Of course, the FDA approval process with its disclosure requirements undermines a manufacturer?s ability to maintain these features as trade secrets. The author will discuss this balance of pros and cons for patenting versus trade secret protection.
image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

1-702-714-7001Extn: 9037

Business & Management Journals


1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

1-702-714-7001 Extn: 9042

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version